Precigen

PGEN

Market cap $1.76B

CFO Harry Thomasian Jr. sold 200,000 shares of Precigen common stock across two transactions for a total value of approximately $1.11 million, based on a weighted average price of $5.57 per share. This transaction reduced his direct ownership by 36%, leaving him with 354,535 shares directly held post-sale, representing an estimated $1.86 million as of the July 1, 2026 market close.

Precigen earns a STRONG BUY rating following the commercial success of PAPZIMEOS and rapid revenue growth. PGEN's AdenoVerse platform underpins a validated, scalable franchise, with PAPZIMEOS now endorsed as first-line therapy for RRP and covered by major US insurers. Management projects cash flow breakeven in 2026, with Wall Street revising EPS and revenue estimates sharply since the 1Q earnings call.

Meg Flippin, Benzinga Staff Writer Data reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs healthcare conference suggests potential of extended surgical holidays for patients with RRP, a rare respiratory disease GERMANTOWN, MD / ACCESS Newswire / June 15, 2026 / Precigen Inc. (NASDAQ:PGEN) has gained an important advantage in the marketing of its new treatment for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease of the respiratory tract. The commercial-stage precision medicines company was just granted orphan drug exclusivity by the FDA for PAPZIMEOS™ (zopapogene imadenovec-drba), its treatment for RRP, a disease that typically requires patients to undergo multiple surgeries each year to remove benign tumors called papillomas that grow in the respiratory tract.

41,884 shares were sold in an open-market transaction for a total of ~$183,000 on May 28, 2026. The sale reduced direct holdings by 7.0%, from 596,419 shares to 554,535 shares, with no change to indirect ownership.

Third annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with RRP GERMANTOWN, Md. and FORT WORTH, Texas, June 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients and the Recurrent Respiratory Papillomatosis Foundation (RRPF), today announced continued collaboration in recognition of the third annual International RRP Awareness Day.

Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP 5 complete responders have ongoing responses beyond 4 years Follow-up is ongoing; median duration of complete response has not yet been reached No new adverse safety events have been observed during long-term follow-up US FDA granted seven-year period of orphan drug market exclusivity to PAPZIMEOS GERMANTOWN, Md., May 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced updated long-term follow-up data from the pivotal study of PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP).

FDA grants orphan drug exclusivity for PAPZIMEOS for the treatment of adults with recurrent respiratory papillomatosis Seven-year period of PAPZIMEOS market exclusivity is effective through August 14, 2032 PAPZIMEOS, the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis, is commercially available in the US GERMANTOWN, Md., May 27, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan drug exclusivity for PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP).

GERMANTOWN, Md., May 26, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the company will participate in two upcoming investor events.